Kewaunee Scientific Reports Results for Fiscal Year and Fourth Quarter

STATESVILLE, N.C., June 28, 2023 /PRNewswire/ — Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its fourth quarter and its fiscal year ended April 30, 2023.

Fiscal Year 2023 Fourth Quarter Results:
Sales during the fourth quarter of fiscal year 2023 were $53,986,000, an increase of 8.6% compared to sales of $49,715,000 from the prior year’s fourth quarter. The increase was a result of higher international segment sales when compared to the prior period due to the continued delivery of several large projects awarded over the course of the past eighteen months.
Pre-tax earnings for the quarter were $2,322,000 compared to $2,345,000 for the prior year period. Net earnings for the quarter were $1,005,000 compared to a net loss of $362,000 for the prior year. EBITDA1 for the quarter was $3,307,000 compared to $2,969,000 for the prior year period. Diluted earnings per share were $0.34, as compared to a diluted loss per share of $0.13 in the prior year’s fourth quarter.
Domestic Segment – Domestic sales for the quarter were $35,123,000, a decrease of 6.9% from sales of $37,720,000 in the prior year period. Net earnings for the domestic segment were $2,402,000 compared to $2,380,000 in the prior year period. Domestic segment EBITDA was $2,991,000 compared to $2,957,000 for the prior year period. During the fourth quarter, the Company fulfilled most of the outstanding performance obligations for the remaining direct orders in its order backlog, the majority of which were priced and executed prior to the broad-based inflation experienced during the previous fiscal year.
International Segment – International sales for the quarter were $18,863,000, an increase of 57.3% from sales of $11,995,000 in the prior year period. This increase in sales was due to the continued delivery of several large projects awarded over the course of the past eighteen months. Net income for the international segment was $1,106,000 compared to $1,020,000 in the prior year period. International segment EBITDA was $1,546,000 compared to $1,456,000 for the prior year period. EBITDA for the quarter was reduced by $293,000, when compared to the previous year period due to a change in the Corporate cost allocation methodology after completing a revised transfer pricing study.
Corporate Segment – Corporate segment net loss was $2,503,000 for the quarter, as compared to $3,762,000 in the prior year period. Corporate segment EBITDA loss for the quarter was $1,230,000, a favorable improvement of 14.8% from corporate segment EBITDA loss of $1,444,000 for the prior year period. The improved EBITDA was driven by the Corporate cost allocation methodology change discussed above, partially offset by higher pension-related expenses.
The Company’s order backlog was $147.9 million on April 30, 2023, decreasing from $153.2 million on January 31, 2023 and $173.9 million on April 30, 2022. This change in backlog is principally driven by the substantial completion of the previously announced Dangote Oil project in Lagos, Nigeria during the fiscal year and a reduction in market demand within the ASEAN marketplace. The Company’s order backlog for the United States and Indian markets finished the year similar to prior year levels as order rates in these markets remain strong.
“Kewaunee delivered one of the best quarters in the Company’s history as our Associates finished fiscal year 2023 on a high note,” said Thomas D. Hull III, Kewaunee’s President, and Chief Executive Officer. “Profitability improved throughout the year as our teams continued to operate the business with excellence.”
“Our domestic team remained focused on supporting our dealer and distribution partners, concluding a year of significant transition. We have materially completed our remaining performance obligations for the previously discussed direct projects, which were priced and awarded prior to the broad-based inflation experienced during the prior fiscal year. We continue to encourage and support our dealer and distribution partners’ investment in their organizations so they can better serve their respective territories and we can grow our businesses together. We ended the year well positioned with a strong go-to-market strategy, a healthy order backlog, and a robust opportunity pipeline.”
“Our international team has been awarded several large, high-profile projects over the past two years. The fourth quarter of fiscal year 2023 was very strong. This resulted in a significant increase in sales when compared to the prior year quarter. The international team wrapped up what was a record year for both sales and earnings for the segment during the fourth quarter. I could not be prouder of how the team performed during the year.”
Fiscal Year 2023 Full Year Results:
Sales during fiscal year 2023 were $219,494,000, an increase of 30.0% compared to sales of $168,872,000 from the prior year. Pre-tax earnings for the fiscal year were $4,498,000 compared to a pre-tax loss of $2,485,000 for the prior year. Net earnings for the fiscal year were $738,000, compared to a net loss of $6,126,000 for the prior year. EBITDA for the fiscal year was $7,517,000 compared to $394,000 for the prior fiscal year. Diluted earnings per share was $0.25, as compared to a loss per share of $2.20 in the prior fiscal year.
Domestic Segment – Domestic sales for the fiscal year were $146,716,000, an increase of 15.7% from sales of $126,848,000 in the prior year. This increase was primarily driven by the pricing of new orders in response to higher raw material input costs. Domestic segment net earnings were $3,408,000 compared to a net loss of $229,000 in the prior fiscal year. Domestic segment EBITDA was $5,802,000 compared to $2,223,000 for the prior year. Domestic segment profitability was negatively impacted during the year by the completion of direct contracts which were priced and awarded prior to the broad-based inflation experienced in the prior fiscal year. Many of these direct contracts were delivered at a loss for the Company.
International Segment – International sales for the fiscal year were $72,778,000, an increase of 73.2% from sales of $42,024,000 in the prior year. The increase in sales was driven by the delivery of several large projects throughout the fiscal year in India, Asia, and Africa. International segment net earnings were $4,511,000 compared to $2,333,000 in the prior fiscal year. International segment EBITDA was $6,650,000 compared to $3,571,000 for the prior year.
Corporate Segment – Corporate segment net loss was $7,181,000 for the fiscal year, as compared to $8,230,000 in the prior fiscal year. Corporate segment EBITDA loss for the fiscal year was $4,935,000, a favorable improvement of 8.6% from corporate segment EBITDA loss of $5,400,000 for the prior year. The favorable change in EBITDA was primarily driven by increased Corporate allocations of $1,172,000 when compared to the prior year due to the change in transfer pricing methodology discussed above, partially offset by higher pension-related expenses and higher operating expenses.
Total cash on hand on April 30, 2023 was $13,815,000, compared to $6,894,000 on April 30, 2022. Working capital was $47,867,000, compared to $49,272,000 on April 30, 2022. Short-term debt was $3,587,000 on April 30, 2023, compared to $1,588,000 on April 30, 2022, and long-term debt was $29,007,000 on April 30, 2023 compared to $29,704,000 on April 30, 2022. The Company’s debt-to-equity ratio on April 30, 2023 was 1.08-to-1, compared to 1.07-to-1 on April 30, 2022.
“Our vision for Kewaunee is to be the global supplier of choice with customers in the laboratory furniture and infrastructure markets,” said Thomas D. Hull III, Kewaunee’s President, and Chief Executive Officer. “In pursuing this vision, we continue to follow the principles that guide our actions:
We will be easy to do business with;We will get closer to our customers;We will do everything with the highest quality; andWe will lead and not follow (we are innovators).””Fiscal year 2023 was a transition year for Kewaunee as we emerged from an extremely disruptive period over the past three years dealing with a global pandemic, rapid broad-based inflation, labor shortages and supply chain disruptions. A testament to the character and drive of Kewaunee’s leadership team and Associates is that, while managing through these challenges, we continued to invest in and evolve our business. The benefits of these decisions began to appear as we moved through the year and our financial performance steadily improved. Kewaunee ends fiscal year 2023 with a strong global management team, a healthy backlog, improved manufacturing capabilities, and end-use markets which continue to prioritize investment in projects that require the products Kewaunee designs and manufactures.”
“Moving forward, Kewaunee will continue to invest in developing world class manufacturing capabilities to support our dealer and distribution partners in growing our businesses together. This investment in our capabilities better positions Kewaunee to be the brand of choice. Kewaunee’s future is bright, and I am excited to continue building on our momentum in fiscal 2024.”
EBITDA and Segment EBITDA Reconciliation
Quarter Ended April 30, 2022
Domestic
International
Corporate
Consolidated
Net Earnings (Loss)
$                  2,380
$                  1,020
$                (3,762)
$                   (362)
Add/(Less):
Interest Expense

13
223
236
Interest Income

(59)
(196)
(255)
Income Taxes

419
2,254
2,673
Depreciation and Amortization
577
63
37
677
EBITDA
$                  2,957
$                  1,456
$                (1,444)
$                  2,969
Quarter Ended April 30, 2023
Domestic
International
Corporate
Consolidated
Net Earnings (Loss)
$                  2,402
$                  1,106
$                (2,503)
$                  1,005
Add/(Less):
Interest Expense

97
447
544
Interest Income

(194)
(1)
(195)
Income Taxes

449
779
1,228
Depreciation and Amortization
589
88
48
725
EBITDA
$                  2,991
$                  1,546
$                (1,230)
$                  3,307
Fiscal Year to Date April 30, 2022
Domestic
International
Corporate
Consolidated
Net Earnings (Loss)
$                   (229)
$                  2,333
$                (8,230)
$                (6,126)
Add/(Less):
Interest Expense

30
602
632
Interest Income

(197)
(202)
(399)
Income Taxes
50
1,129
2,339
3,518
Depreciation and Amortization
2,402
276
91
2,769
EBITDA
$                  2,223
$                  3,571
$                (5,400)
$                     394
Fiscal Year to Date April 30, 2023
Domestic
International
Corporate
Consolidated
Net Earnings (Loss)
$                  3,408
$                  4,511
$                (7,181)
$                     738
Add/(Less):
Interest Expense

210
1,524
1,734
Interest Income

(603)
(358)
(961)
Income Taxes

2,250
889
3,139
Depreciation and Amortization
2,394
282
191
2,867
EBITDA
$                  5,802
$                  6,650
$                (4,935)
$                  7,517
About Non-GAAP Measures
EBITDA and Segment EBITDA are calculated as net earnings (loss), less interest expense and interest income, income taxes, depreciation, and amortization. We believe EBITDA and Segment EBITDA allow management and investors to compare our performance to other companies on a consistent basis without regard to depreciation and amortization, which can vary significantly between companies depending upon many factors. EBITDA and Segment EBITDA are not calculations based upon generally accepted accounting principles, and the method for calculating EBITDA and Segment EBITDA can vary among companies. The amounts included in the EBITDA and Segment EBITDA calculations, however, are derived from amounts included in the historical statements of operations. EBITDA and Segment EBITDA should not be considered as alternatives to net earnings (loss) or operating earnings (loss) as an indicator of the Company’s operating performance, or as an alternative to operating cash flows as a measure of liquidity.
About Kewaunee Scientific
Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company’s products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.
The Company’s corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. Kewaunee Scientific’s website is located at http://www.kewaunee.com. 
This press release contains statements that the Company believes to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company’s future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “predict,” “believe” and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers’ required delivery schedules; risks related to fluctuations in the Company’s operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, natural disasters and other Force Majeure events. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders’ interest. Many important factors that could cause such a difference are described under the caption “Risk Factors,” in Item 1A of our Annual Report on Form 10-K for the most recent fiscal year ended April 30, which you should review carefully, and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. These reports are available on our investor relations website at www.kewaunee.com and on the SEC website at www.sec.gov. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise. 
Contact:           Donald T. Gardner III704/871-3274
1 EBITDA is a non-GAAP financial measure. See the table below for a reconciliation of EBITDA and segment EBITDA to net earnings (loss), the most directly comparable GAAP measure.
 
Kewaunee Scientific Corporation
Consolidated Statements of Operations
($ and shares in thousands, except per share amounts)
Three months ended
Twelve months ended
April 30,
April 30,
2023
2022
2023
2022
Net sales
$           53,986
$           49,715
$        219,494
$        168,872
Cost of products sold
43,625
40,388
183,906
144,652
Gross profit
10,361
9,327
35,588
24,220
Operating expenses
7,660
7,086
30,224
26,828
Operating earnings (loss)
2,701
2,241
5,364
(2,608)
Pension (expense) income
(18)
89
(71)
355
Other income, net
183
251
939
400
Interest expense
(544)
(236)
(1,734)
(632)
Earnings (loss) before income taxes
2,322
2,345
4,498
(2,485)
Income tax expense
1,228
2,673
3,139
3,518
Net earnings (loss)
1,094
(328)
1,359
(6,003)
Less: Net earnings attributable to the non-controlling interest
89
34
621
123
Net earnings (loss) attributable to Kewaunee Scientific Corporation
$             1,005
$               (362)
$                738
$           (6,126)
Net earnings (loss) per share attributable to
    Kewaunee Scientific Corporation stockholders
       Basic
$0.36
($0.13)
$0.26
($2.20)
       Diluted
$0.34
($0.13)
$0.25
($2.20)
Weighted average number of common shares outstanding
       Basic
2,830
2,790
2,824
2,786
       Diluted
2,928
2,790
2,902
2,786
 
 
Kewaunee Scientific Corporation
Condensed Consolidated Balance Sheets
($ in thousands)
April 30,
 April 30,
2023
2022
Assets
Cash and cash equivalents
$             8,078
$             4,433
Restricted cash
5,737
2,461
Receivables, less allowances
46,081
41,254
Inventories
21,889
23,796
Note receivable

13,457
Prepaid expenses and other current assets
6,135
6,164
    Total Current Assets
87,920
91,565
Net property, plant and equipment
16,402
15,121
Right of use assets
9,170
7,573
Other assets
5,406
4,514
Total Assets
$        118,898
$        118,773
Liabilities and Stockholders’ Equity
Short-term borrowings
$             3,587
$             1,588
Current portion of financing lease liabilities
85
126
Current portion of operating lease liabilities
1,967
1,319
Current portion of financing liability
642
575
Accounts payable
23,599
27,316
Other current liabilities
10,173
11,369
    Total Current Liabilities
40,053
42,293
Long-term portion of financing lease liabilities
148
228
Long-term portion of operating lease liabilities
7,136
6,179
Long-term portion of financing liability
28,132
28,775
Other non-current liabilities
4,944
5,118
    Total Liabilities
80,413
82,593
Kewaunee Scientific Corporation Equity
37,409
35,694
Non-controlling interest
1,076
486
    Total Stockholders’ Equity
38,485
36,180
Total Liabilities and Stockholders’ Equity
$        118,898
$        118,773
 
 

View original content to download multimedia:https://www.prnewswire.com/news-releases/kewaunee-scientific-reports-results-for-fiscal-year-and-fourth-quarter-301866320.html
SOURCE Kewaunee Scientific Corporation 

STATESVILLE, N.C., June 28, 2023 /PRNewswire/ — Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its fourth quarter and its fiscal year ended April 30, 2023.

Fiscal Year 2023 Fourth Quarter Results:

Sales during the fourth quarter of fiscal year 2023 were $53,986,000, an increase of 8.6% compared to sales of $49,715,000 from the prior year’s fourth quarter. The increase was a result of higher international segment sales when compared to the prior period due to the continued delivery of several large projects awarded over the course of the past eighteen months.

Pre-tax earnings for the quarter were $2,322,000 compared to $2,345,000 for the prior year period. Net earnings for the quarter were $1,005,000 compared to a net loss of $362,000 for the prior year. EBITDA1 for the quarter was $3,307,000 compared to $2,969,000 for the prior year period. Diluted earnings per share were $0.34, as compared to a diluted loss per share of $0.13 in the prior year’s fourth quarter.

Domestic Segment – Domestic sales for the quarter were $35,123,000, a decrease of 6.9% from sales of $37,720,000 in the prior year period. Net earnings for the domestic segment were $2,402,000 compared to $2,380,000 in the prior year period. Domestic segment EBITDA was $2,991,000 compared to $2,957,000 for the prior year period. During the fourth quarter, the Company fulfilled most of the outstanding performance obligations for the remaining direct orders in its order backlog, the majority of which were priced and executed prior to the broad-based inflation experienced during the previous fiscal year.

International Segment – International sales for the quarter were $18,863,000, an increase of 57.3% from sales of $11,995,000 in the prior year period. This increase in sales was due to the continued delivery of several large projects awarded over the course of the past eighteen months. Net income for the international segment was $1,106,000 compared to $1,020,000 in the prior year period. International segment EBITDA was $1,546,000 compared to $1,456,000 for the prior year period. EBITDA for the quarter was reduced by $293,000, when compared to the previous year period due to a change in the Corporate cost allocation methodology after completing a revised transfer pricing study.

Corporate Segment – Corporate segment net loss was $2,503,000 for the quarter, as compared to $3,762,000 in the prior year period. Corporate segment EBITDA loss for the quarter was $1,230,000, a favorable improvement of 14.8% from corporate segment EBITDA loss of $1,444,000 for the prior year period. The improved EBITDA was driven by the Corporate cost allocation methodology change discussed above, partially offset by higher pension-related expenses.

The Company’s order backlog was $147.9 million on April 30, 2023, decreasing from $153.2 million on January 31, 2023 and $173.9 million on April 30, 2022. This change in backlog is principally driven by the substantial completion of the previously announced Dangote Oil project in Lagos, Nigeria during the fiscal year and a reduction in market demand within the ASEAN marketplace. The Company’s order backlog for the United States and Indian markets finished the year similar to prior year levels as order rates in these markets remain strong.

“Kewaunee delivered one of the best quarters in the Company’s history as our Associates finished fiscal year 2023 on a high note,” said Thomas D. Hull III, Kewaunee’s President, and Chief Executive Officer. “Profitability improved throughout the year as our teams continued to operate the business with excellence.”

“Our domestic team remained focused on supporting our dealer and distribution partners, concluding a year of significant transition. We have materially completed our remaining performance obligations for the previously discussed direct projects, which were priced and awarded prior to the broad-based inflation experienced during the prior fiscal year. We continue to encourage and support our dealer and distribution partners’ investment in their organizations so they can better serve their respective territories and we can grow our businesses together. We ended the year well positioned with a strong go-to-market strategy, a healthy order backlog, and a robust opportunity pipeline.”

“Our international team has been awarded several large, high-profile projects over the past two years. The fourth quarter of fiscal year 2023 was very strong. This resulted in a significant increase in sales when compared to the prior year quarter. The international team wrapped up what was a record year for both sales and earnings for the segment during the fourth quarter. I could not be prouder of how the team performed during the year.”

Fiscal Year 2023 Full Year Results:

Sales during fiscal year 2023 were $219,494,000, an increase of 30.0% compared to sales of $168,872,000 from the prior year. Pre-tax earnings for the fiscal year were $4,498,000 compared to a pre-tax loss of $2,485,000 for the prior year. Net earnings for the fiscal year were $738,000, compared to a net loss of $6,126,000 for the prior year. EBITDA for the fiscal year was $7,517,000 compared to $394,000 for the prior fiscal year. Diluted earnings per share was $0.25, as compared to a loss per share of $2.20 in the prior fiscal year.

Domestic Segment – Domestic sales for the fiscal year were $146,716,000, an increase of 15.7% from sales of $126,848,000 in the prior year. This increase was primarily driven by the pricing of new orders in response to higher raw material input costs. Domestic segment net earnings were $3,408,000 compared to a net loss of $229,000 in the prior fiscal year. Domestic segment EBITDA was $5,802,000 compared to $2,223,000 for the prior year. Domestic segment profitability was negatively impacted during the year by the completion of direct contracts which were priced and awarded prior to the broad-based inflation experienced in the prior fiscal year. Many of these direct contracts were delivered at a loss for the Company.

International Segment – International sales for the fiscal year were $72,778,000, an increase of 73.2% from sales of $42,024,000 in the prior year. The increase in sales was driven by the delivery of several large projects throughout the fiscal year in India, Asia, and Africa. International segment net earnings were $4,511,000 compared to $2,333,000 in the prior fiscal year. International segment EBITDA was $6,650,000 compared to $3,571,000 for the prior year.

Corporate Segment – Corporate segment net loss was $7,181,000 for the fiscal year, as compared to $8,230,000 in the prior fiscal year. Corporate segment EBITDA loss for the fiscal year was $4,935,000, a favorable improvement of 8.6% from corporate segment EBITDA loss of $5,400,000 for the prior year. The favorable change in EBITDA was primarily driven by increased Corporate allocations of $1,172,000 when compared to the prior year due to the change in transfer pricing methodology discussed above, partially offset by higher pension-related expenses and higher operating expenses.

Total cash on hand on April 30, 2023 was $13,815,000, compared to $6,894,000 on April 30, 2022. Working capital was $47,867,000, compared to $49,272,000 on April 30, 2022. Short-term debt was $3,587,000 on April 30, 2023, compared to $1,588,000 on April 30, 2022, and long-term debt was $29,007,000 on April 30, 2023 compared to $29,704,000 on April 30, 2022. The Company’s debt-to-equity ratio on April 30, 2023 was 1.08-to-1, compared to 1.07-to-1 on April 30, 2022.

“Our vision for Kewaunee is to be the global supplier of choice with customers in the laboratory furniture and infrastructure markets,” said Thomas D. Hull III, Kewaunee’s President, and Chief Executive Officer. “In pursuing this vision, we continue to follow the principles that guide our actions:

We will be easy to do business with;We will get closer to our customers;We will do everything with the highest quality; andWe will lead and not follow (we are innovators).”

“Fiscal year 2023 was a transition year for Kewaunee as we emerged from an extremely disruptive period over the past three years dealing with a global pandemic, rapid broad-based inflation, labor shortages and supply chain disruptions. A testament to the character and drive of Kewaunee’s leadership team and Associates is that, while managing through these challenges, we continued to invest in and evolve our business. The benefits of these decisions began to appear as we moved through the year and our financial performance steadily improved. Kewaunee ends fiscal year 2023 with a strong global management team, a healthy backlog, improved manufacturing capabilities, and end-use markets which continue to prioritize investment in projects that require the products Kewaunee designs and manufactures.”

“Moving forward, Kewaunee will continue to invest in developing world class manufacturing capabilities to support our dealer and distribution partners in growing our businesses together. This investment in our capabilities better positions Kewaunee to be the brand of choice. Kewaunee’s future is bright, and I am excited to continue building on our momentum in fiscal 2024.”

EBITDA and Segment EBITDA Reconciliation

Quarter Ended April 30, 2022

Domestic

International

Corporate

Consolidated

Net Earnings (Loss)

$                  2,380

$                  1,020

$                (3,762)

$                   (362)

Add/(Less):

Interest Expense

13

223

236

Interest Income

(59)

(196)

(255)

Income Taxes

419

2,254

2,673

Depreciation and Amortization

577

63

37

677

EBITDA

$                  2,957

$                  1,456

$                (1,444)

$                  2,969

Quarter Ended April 30, 2023

Domestic

International

Corporate

Consolidated

Net Earnings (Loss)

$                  2,402

$                  1,106

$                (2,503)

$                  1,005

Add/(Less):

Interest Expense

97

447

544

Interest Income

(194)

(1)

(195)

Income Taxes

449

779

1,228

Depreciation and Amortization

589

88

48

725

EBITDA

$                  2,991

$                  1,546

$                (1,230)

$                  3,307

Fiscal Year to Date April 30, 2022

Domestic

International

Corporate

Consolidated

Net Earnings (Loss)

$                   (229)

$                  2,333

$                (8,230)

$                (6,126)

Add/(Less):

Interest Expense

30

602

632

Interest Income

(197)

(202)

(399)

Income Taxes

50

1,129

2,339

3,518

Depreciation and Amortization

2,402

276

91

2,769

EBITDA

$                  2,223

$                  3,571

$                (5,400)

$                     394

Fiscal Year to Date April 30, 2023

Domestic

International

Corporate

Consolidated

Net Earnings (Loss)

$                  3,408

$                  4,511

$                (7,181)

$                     738

Add/(Less):

Interest Expense

210

1,524

1,734

Interest Income

(603)

(358)

(961)

Income Taxes

2,250

889

3,139

Depreciation and Amortization

2,394

282

191

2,867

EBITDA

$                  5,802

$                  6,650

$                (4,935)

$                  7,517

About Non-GAAP Measures

EBITDA and Segment EBITDA are calculated as net earnings (loss), less interest expense and interest income, income taxes, depreciation, and amortization. We believe EBITDA and Segment EBITDA allow management and investors to compare our performance to other companies on a consistent basis without regard to depreciation and amortization, which can vary significantly between companies depending upon many factors. EBITDA and Segment EBITDA are not calculations based upon generally accepted accounting principles, and the method for calculating EBITDA and Segment EBITDA can vary among companies. The amounts included in the EBITDA and Segment EBITDA calculations, however, are derived from amounts included in the historical statements of operations. EBITDA and Segment EBITDA should not be considered as alternatives to net earnings (loss) or operating earnings (loss) as an indicator of the Company’s operating performance, or as an alternative to operating cash flows as a measure of liquidity.

About Kewaunee Scientific

Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company’s products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.

The Company’s corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. Kewaunee Scientific’s website is located at http://www.kewaunee.com

This press release contains statements that the Company believes to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company’s future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “predict,” “believe” and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers’ required delivery schedules; risks related to fluctuations in the Company’s operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, natural disasters and other Force Majeure events. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders’ interest. Many important factors that could cause such a difference are described under the caption “Risk Factors,” in Item 1A of our Annual Report on Form 10-K for the most recent fiscal year ended April 30, which you should review carefully, and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. These reports are available on our investor relations website at www.kewaunee.com and on the SEC website at www.sec.gov. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise. 

Contact:          
Donald T. Gardner III
704/871-3274

1 EBITDA is a non-GAAP financial measure. See the table below for a reconciliation of EBITDA and segment EBITDA to net earnings (loss), the most directly comparable GAAP measure.

 

Kewaunee Scientific Corporation

Consolidated Statements of Operations

($ and shares in thousands, except per share amounts)

Three months ended

Twelve months ended

April 30,

April 30,

2023

2022

2023

2022

Net sales

$           53,986

$           49,715

$        219,494

$        168,872

Cost of products sold

43,625

40,388

183,906

144,652

Gross profit

10,361

9,327

35,588

24,220

Operating expenses

7,660

7,086

30,224

26,828

Operating earnings (loss)

2,701

2,241

5,364

(2,608)

Pension (expense) income

(18)

89

(71)

355

Other income, net

183

251

939

400

Interest expense

(544)

(236)

(1,734)

(632)

Earnings (loss) before income taxes

2,322

2,345

4,498

(2,485)

Income tax expense

1,228

2,673

3,139

3,518

Net earnings (loss)

1,094

(328)

1,359

(6,003)

Less: Net earnings attributable to the non-controlling interest

89

34

621

123

Net earnings (loss) attributable to Kewaunee Scientific Corporation

$             1,005

$               (362)

$                738

$           (6,126)

Net earnings (loss) per share attributable to

    Kewaunee Scientific Corporation stockholders

       Basic

$0.36

($0.13)

$0.26

($2.20)

       Diluted

$0.34

($0.13)

$0.25

($2.20)

Weighted average number of common shares outstanding

       Basic

2,830

2,790

2,824

2,786

       Diluted

2,928

2,790

2,902

2,786

 

 

Kewaunee Scientific Corporation

Condensed Consolidated Balance Sheets

($ in thousands)

April 30,

 April 30,

2023

2022

Assets

Cash and cash equivalents

$             8,078

$             4,433

Restricted cash

5,737

2,461

Receivables, less allowances

46,081

41,254

Inventories

21,889

23,796

Note receivable

13,457

Prepaid expenses and other current assets

6,135

6,164

    Total Current Assets

87,920

91,565

Net property, plant and equipment

16,402

15,121

Right of use assets

9,170

7,573

Other assets

5,406

4,514

Total Assets

$        118,898

$        118,773

Liabilities and Stockholders’ Equity

Short-term borrowings

$             3,587

$             1,588

Current portion of financing lease liabilities

85

126

Current portion of operating lease liabilities

1,967

1,319

Current portion of financing liability

642

575

Accounts payable

23,599

27,316

Other current liabilities

10,173

11,369

    Total Current Liabilities

40,053

42,293

Long-term portion of financing lease liabilities

148

228

Long-term portion of operating lease liabilities

7,136

6,179

Long-term portion of financing liability

28,132

28,775

Other non-current liabilities

4,944

5,118

    Total Liabilities

80,413

82,593

Kewaunee Scientific Corporation Equity

37,409

35,694

Non-controlling interest

1,076

486

    Total Stockholders’ Equity

38,485

36,180

Total Liabilities and Stockholders’ Equity

$        118,898

$        118,773

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/kewaunee-scientific-reports-results-for-fiscal-year-and-fourth-quarter-301866320.html

SOURCE Kewaunee Scientific Corporation

 

Spread The Word...

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

LATEST POST

Yamaha YH-5000SE headphones use the iconic ORTHODYNAMIC drivers for stunning sound
Yamaha YH-5000SE headphones use the iconic ORTHODYNAMIC drivers for stunning sound
Sony BRAVIA Theater Bar 9 Dolby Atmos Soundbar delivers convention-defying sound
Sony BRAVIA Theater Bar 9 Dolby Atmos Soundbar delivers convention-defying sound
Voon Soccer Rebounder elevates your training whether you’re alone or with a team
Voon Soccer Rebounder elevates your training whether you’re alone or with a team
The James Lab The Burwell Click Pen has an EDC-friendly shape and style for daily use
The James Lab The Burwell Click Pen has an EDC-friendly shape and style for daily use
Panic Playdate Stereo Dock enhances your desk with its design and 4-in-1 functionality
Panic Playdate Stereo Dock enhances your desk with its design and 4-in-1 functionality
The Most Innovative Everyday Carry Releases This Week
The Most Innovative Everyday Carry Releases This Week

CONTRIBUTE

Please contribute and support me to keep this website alive. Any BIG or small amount contributed is very much appreciated.

Thank you!